Analyst coverage on Xbrane Biopharma

In accordance with the communicated statement in our previous shareholder letter, we inform that the Xbrane share is being analysed by the international research house Edison, which has issued a initial short abstract "quick view" to be followed by a full initiating coverage before the years end. Edison is an independent investment research firm based in London, with over 100 analysts that provide services to more than 420 retained corporate and investor clients across the globe. The quick view can be accessed at: http://www.edisoninvestmentresearch.com/research/report/xbrane/full/

To provide analyst coverage targeted primarily to Swedish investors Jarl Securities has issued an analysis on Xbrane Biopharma which can can be accessed at: http://www.aktiespararna.se/analysguiden/Hitta-Bolag/Halsovard/XBRANE/Analyser/2016/Infor-potentiell-lansering-2017-/

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see www.xbrane.com.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com